

CURRENT REPORT 16/2021

May 20, 2021

Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021

The Management Board of Ryvu Therapeutics S.A. ("Company") hereby announces that on May 19, 2021 The American Society of Clinical Oncology ("ASCO") has published a conference abstract containing information on an ongoing phase I/II clinical trial of SEL24 (MEN1703), a first in class, orally available, dual PIM/FLT3 inhibitor.

ASCO Poster details:

- Updated results from DIAMOND-01 (CLI24-001) trial: a Phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.
- Abstract Code. 7023, Poster presentation

The abstract is available on the ASCO website: <https://www.asco.org/>

The ASCO Annual Meeting 2021, which will take place on June 4-8, 2021, is considered one of the most important scientific events, gathering researchers, as well as potential clients and business partners - biotechnology and pharmaceutical companies and industry investors.

Legal basis: art. 17 ust. 1 MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board
- Setareh Shamsili – Vice President of the Management Board